Abstract
Hepatocellular carcinoma (HCC) is one of the most lethal tumors and has high malignancy and low survival. Generally, the glucose metabolism in malignant tumors is significantly different from normal tissues, which show high uptake. However, it varies greatly in HCC. Low glucose metabolism is often observed in well- and moderately differentiated HCC. Furthermore, glycolysis has been widely confirmed to be a nonspecific biological phenomenon in malignant tumors, including HCC, by positron emission tomography (PET) combined with computed tomography using 18-fluorine-fluorodeoxyglucose (a glucose analogue). However, to determine the value of PET and develop new effective drugs and molecular probes, we need to comprehensively understand how hepatocellular cancer cells use glucose to supply energy. In this article, we reviewed and summarized the glycometabolism characteristics of HCC and their application in PET. Key words: Carcinoma, hepatocellular; Positron emission tomography; Glycometabolism; Transportprotein
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
